1. Takeuchi Y, Murahashi S, Hara Y, Ueda M: Possible Cerebral Vasculitis in a Case with Rheumatoid Arthritis. Intern Med, 60: 935-940, 2021

2. Matsushita H, Isoguchi A, Okada M, Masuda T, Misumi Y, Ichiki Y, Ueda M, Ando Y: Amyloid fibril formation is suppressed in microgravity. Biochem Biophys Rep, 25: 100875, 2021

3. Yi K, Inatomi Y, Nakajima M, Yonehara T, Ueda M: Reliability of the Modified Rankin Scale Assessment Using a Simplified Questionnaire in Japanese. J Stroke Cerebrovasc Dis, 30: 105517, 2021

4. Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen A, Schmidt H, Berk J, López I, Dispenzieri A, Conceição I, Slama M, Gillmore J, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei M, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan T, Ueda M, Aldinc E, Wang J, White M, Vest J, Berber E, Sweetser M, Coelho T: Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol, 20: 49-59, 2021

5. Usuku H, Yamamoto E, Nishi M, Komorita T, Takae M, Nishihara T, Oike F, Ishii M, Fujisue K, Sueta D, Araki S, Takashio S, Oda S, Misumi Y, Ueda M, Nakamura T, Kawano H, Soejima H, Sakamoto K, Kaikita K, Ando Y, Matsui H, Tsujita K: Temporal change in longitudinal strain after domino liver transplantation with liver grafts explanted from patients with hereditary amyloidogenic transthyretin amyloidosis. Circ Rep, 2: 730-738, 2020

6. Usuku H, Takashio S, Yamamoto E, Kinoshita Y, Nishi M, Oike F, Marume K, Hirakawa K, Tabata N, Oda S, Misumi Y, Ueda M, Kawano H, Kaikita K, Matsushita K, Ando Y, Matsui H, Tsujita K: Usefulness of relative apical longitudinal strain index to predict positive 99mTc-labeled pyrophosphate scintigraphy findings in advanced-age patients with suspected transthyretin amyloid cardiomyopathy. Echocardiography, 37: 1774-1783, 2020

7. Hosoda Y, Ueda M, Takaki J, Okamoto K, Yamashita T, Fukui T: Early progression of aortic stenosis associated with iatrogenic variant transthyretin amyloidosis after domino liver transplantation. JACC Case Rep, 2: 1155-1160, 2020

8. Yamashita T, Ueda M, Sekijima Y, Yoshinaga T, Kodaira M, Koike H, Katsuno M, Sobue G, Zhang X, White M, Sweetser M, Wang J, Ando Y: Patisiran, an RNAi therapeutic for patients with hereditary transthyretin-mediated amyloidosis: sub-analysis in Japanese patients from the APOLLO study. Neurol Clin Neurosci, 8: 251–260, 2020

9. Yamada T, Takashio S, Arima Y, Nishi M, Morioka M, Hirakawa K, Hanatani S, Fujisue K, Yamanaga K, Kanazawa H, Sueta D, Araki S, Usuku H, Nakamura T, Suzuki S,  Yamamoto E,  Ueda M, Kaikita K, Tsujita K: Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail, 7: 2829-2837, 2020

10. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, Koyama J, Sano M, Sekijima Y, Tahara N, Tsukada N, Tsujita K, Tsutsui H, Tomita T, Amano M, Endo J, Okada A, Oda S, Takashio S, Baba Y, Misumi Y, Yazaki M, Anzai T, Ando Y, Isobe M, Kimura T, Fukuda K: JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. Circ J, 84: 1610-1671, 2020 

11. Ma Y, Ueda M, Ueda A, Shinriki S, Nagatoshi A, Isoguchi A, Okada M, Tasaki M, Nomura T, Inoue Y, Masuda T, Misumi Y, Yamashita T, Matsui H, Ando Y: Novel dot-blot assay for detection of vascular Notch3 aggregates in patients with CADASIL. J Neurol Sci, 415: 116931, 2020

12. Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, Ando Y: Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci, 414: 116813, 2020 

13. González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D: Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (Journal of Neurology, (2020), 267, 3, (703-712), 10.1007/s00415-019-09602-8). J Neurol, 267: 713-714, 2020 

14. González-Duarte A, Berk JL, Quan D, Mauermann ML, Schmidt HH, Polydefkis M, Waddington-Cruz M, Ueda M, Conceição IM, Kristen AV, Coelho T, Cauquil CA, Tard C, Merkel M, Aldinc E, Chen J, Sweetser MT, Wang JJ, Adams D: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. J Neurol, 267: 703-712, 2020 

15. Ishii T, Hirano Y, Matsumoto N, Takata A, Sekijima Y, Ueda M, Ando Y: Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance. Clin Ther, 42：1728-1737, 2020  

16. Ochi Y, Kubo T, Nakashima Y, Baba Y, Hirota T, Yamasaki N, Yamashita T, Ueda M, Ando Y, Kitaoka H: Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy. J Cardiol, 75: 12-19, 2020